Revance Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
12.08.24	Revance Therapeutics To Merge With Crown Lab In Transaction Valued At $924 Mln (RTTNews)
04.03.24	Revance Prices Offering Of 16 Mln Shares At $6.25/Share; Stock Drops (RTTNews)
04.03.24	Revance Proposes Public Offering Of $100 Mln Of Shares; Stock Down Over 8% In Pre-market (RTTNews)
02.02.24	Revance Therapeutics Receives Permanent J-Code For DAXXIFY - Quick Facts (RTTNews)
14.08.23	Revance Therapeutics Says FDA Approves DAXXIFY For Injection To Treat Cervical Dystonia In Adults (RTTNews)
17.11.22	Nanostics Announces New Member of Board of Directors (PR Newswire)
07.10.22	These Biotech Stocks Hit New 52-week High, Were They In Your Portfolio? (RTTNews)
13.09.22	Pre-market Movers: AKRO, ETNB, CMRA, RENT, CRDF… (RTTNews)
13.09.22	Revance Therapeutics Prices Upsized Underwritten Public Offering Of 8 Mln Shares At $25.00/shr (RTTNews)
08.09.22	Revance Therapeutics Announces FDA Approval Of DAXXIFY - Quick Facts (RTTNews)
27.08.22	Biotech Stocks Facing FDA Decision In September (RTTNews)
26.01.22	ROSEN, A LEADING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC (PR Newswire)
17.01.22	ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - RVNC (PR Newswire)
09.01.22	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RVNC (PR Newswire)
01.01.22	ROSEN, NATIONAL TRIAL COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - RVNC (PR Newswire)
24.12.21	ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC (PR Newswire)
14.12.21	ROSEN, A LONGSTANDING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RVNC (PR Newswire)
19.10.21	RVNC EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - RVNC (PR Newswire)
18.10.21	Pre-market Movers: JCS, VALN, RVNC, HX, AVDL… (RTTNews)
16.09.21	Revance To Present Results From Phase 3 Trial Of DaxibotulinumtoxinA On Cervical Dystonia (RTTNews)
08.01.21	ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data (RTTNews)
10.11.20	Pre-market Movers In Healthcare Sector: ALT, AFMD, BNTX, PFE, AZN, SUPN… (RTTNews)
10.11.20	ARNA Falls Short Of ADVICE, PFE's COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy (RTTNews)
26.10.20	Biotech Stocks Facing FDA Decision In November 2020 (RTTNews)
16.09.20	ARPO To Report Glaucoma Trial Data In Q4, ARDX To Face FDA In April, PFE's Pipeline Update (RTTNews)
06.02.20	Stock Alert: Revance Therapeutics (RVNC) Brings Smile To Investors (RTTNews)
15.10.19	RETA Surges On Trial Data, RVNC On Track, All Eyes On RLMD Today (RTTNews)
06.08.19	ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN (RTTNews)
09.04.19	Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing (Businesswire)
08.04.19	SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference (Businesswire)
02.04.19	Revance to Participate in the Needham Healthcare Conference (Businesswire)
05.03.19	Revance to Participate in Upcoming Investor Conferences (Businesswire)
26.02.19	Revance Releases Fourth Quarter and Full Year 2018 Results (Businesswire)
12.02.19	Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019 (Businesswire)
22.01.19	Revance Announces Closing of Public Offering of Common Stock (Businesswire)
17.01.19	Revance Announces Pricing of Public Offering of Common Stock (Businesswire)
15.01.19	Revance Announces Proposed Public Offering of Common Stock (Businesswire)
15.01.19	Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference (Businesswire)
07.01.19	Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones (Businesswire)
04.12.18	Revance Announces China Market License Agreement with Fosun Pharma for RT002 (Businesswire)
04.12.18	Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program (Businesswire)
20.11.18	Revance to Participate in Upcoming Investor Conferences (Businesswire)
07.11.18	Revance to Participate in the Credit Suisse Healthcare Conference (Businesswire)
01.11.18	Revance Releases Third Quarter 2018 Results (Businesswire)
18.10.18	Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018 (Businesswire)
11.10.18	Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer (Businesswire)
20.09.18	Revance Receives Great Place to Work Certification (Businesswire)
02.08.18	Revance Releases Second Quarter 2018 Results (Businesswire)
19.07.18	Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Revance Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten